MaxCyte (NASDAQ:MXCT) is a commercial-stage biotechnology company specializing in advanced cell-engineering platforms that enable research, development and manufacturing of cellular therapies and life sciences products. Founded in 1998 and headquartered in Gaithersburg, Maryland, the company’s core technology leverages Flow Electroporation to introduce a broad range of biologics—such as mRNA, DNA, proteins and ribonucleoprotein complexes—into diverse cell types with high viability and scalability. MaxCyte’s platform is designed to support both preclinical applications and large-scale commercial manufacturing, addressing critical bottlenecks in next-generation cell and gene therapy development.
The company offers a suite of instrument systems—STX®, ATx®, and GTx®—alongside proprietary disposable processing assemblies and optimized buffer reagents, which together form an integrated workflow for electroporation-based cell engineering. These instruments support multiple modalities, including CRISPR gene editing, mRNA transfection and CAR-T cell production. In addition to product sales, MaxCyte generates service revenues through collaborations and license agreements with leading pharmaceutical and biotechnology firms, providing customized process development and clinical manufacturing support under its Cell Therapy Development Services (CTDS) business line.
MaxCyte serves a global customer base spanning North America, Europe and Asia, with strategic partnerships and collaborations that include major industry players in oncology, rare diseases and regenerative medicine. The company’s technology has been utilized in numerous clinical trials, underpinning investigational therapies that target areas such as solid tumors, immuno-oncology and genetic disorders. Its wide-ranging application potential and regulatory compliance credentials have established MaxCyte as a preferred cell-engineering provider for organizations seeking to accelerate their therapeutic pipelines.
Under the leadership of President and Chief Executive Officer Doug Doerfler, MaxCyte continues to expand its product portfolio and service offerings while pursuing new strategic alliances. The company’s management team combines expertise in engineering, pharmaceutical development and commercial operations, driving growth initiatives that capitalize on rising demand for cell and gene therapy solutions. With a track record of innovation and a diverse revenue model, MaxCyte is positioned to play a pivotal role in the evolving landscape of advanced biologics and personalized medicine.
